Novavax Stock Performance
| NVAX Stock | USD 7.17 0.17 2.43% |
The company secures a Beta (Market Risk) of 2.25, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Novavax will likely underperform. Novavax right now secures a risk of 4.37%. Please verify Novavax sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to decide if Novavax will be following its current price movements.
Risk-Adjusted Performance
Modest
Weak | Strong |
Over the last 90 days Novavax has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Novavax is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 2.43 | Five Day Return 3.17 | Year To Date Return (16.34) | Ten Year Return (97.11) | All Time Return (91.04) |
Last Split Factor 1:20 | Dividend Date 2019-05-10 | Last Split Date 2019-05-10 |
1 | STAT Pharmalittle Were reading about Sanofi buying Blueprint, a Bristol deal with BioNTech and more | 06/02/2025 |
2 | Acquisition by Alton Gregg H of 3420 shares of Novavax at 4.9 subject to Rule 16b-3 | 06/05/2025 |
3 | Novavaxs COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of... | 06/11/2025 |
4 | Why Is Cidara Therapeutics Stock Trading Higher On Monday | 06/23/2025 |
5 | Is Most-Watched Stock Novavax, Inc. Worth Betting on Now | 07/01/2025 |
6 | FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff | 07/02/2025 |
7 | RFK Jr.s top FDA vaccine official restricts 2 COVID vaccine approvals against advice of agency scientists | 07/03/2025 |
8 | The Secret Campaign To Stop RFK Jr. | 07/07/2025 |
9 | Citi Initiates Coverage of Novavax With a Sell Rating | 07/10/2025 |
10 | 2 Beaten-Down Stocks That Havent Hit Rock Bottom Yet | 07/11/2025 |
11 | Is Trending Stock Novavax, Inc. a Buy Now | 07/14/2025 |
12 | Novavax Inc. Stock Analysis and Forecast - Superior investment outcomes - Jammu Links News | 07/18/2025 |
13 | What analysts say about Novavax Inc. stock - Exceptional trading performance - Autocar Professional | 07/21/2025 |
| Begin Period Cash Flow | 583.8 M | |
| Total Cashflows From Investing Activities | -204 M |
Novavax Relative Risk vs. Return Landscape
If you would invest 747.00 in Novavax on April 23, 2025 and sell it today you would lose (30.00) from holding Novavax or give up 4.02% of portfolio value over 90 days. Novavax is currently generating 0.0251% in daily expected returns and assumes 4.3712% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Novavax, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Novavax Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novavax's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novavax, and traders can use it to determine the average amount a Novavax's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0057
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NVAX |
Estimated Market Risk
| 4.37 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Novavax is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novavax by adding Novavax to a well-diversified portfolio.
Novavax Fundamentals Growth
Novavax Stock prices reflect investors' perceptions of the future prospects and financial health of Novavax, and Novavax fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novavax Stock performance.
| Return On Equity | -8.98 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.38 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | 630.97 M | ||||
| Shares Outstanding | 161.97 M | ||||
| Price To Earning | (1.36) X | ||||
| Price To Book | 49.52 X | ||||
| Price To Sales | 0.93 X | ||||
| Revenue | 682.16 M | ||||
| Gross Profit | 732.56 M | ||||
| EBITDA | (108.04 M) | ||||
| Net Income | (187.5 M) | ||||
| Cash And Equivalents | 1.28 B | ||||
| Cash Per Share | 16.31 X | ||||
| Total Debt | 230.42 M | ||||
| Debt To Equity | 8.24 % | ||||
| Current Ratio | 1.05 X | ||||
| Book Value Per Share | (0.47) X | ||||
| Cash Flow From Operations | (87.26 M) | ||||
| Earnings Per Share | 2.75 X | ||||
| Market Capitalization | 1.16 B | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (5.01 B) | ||||
| Working Capital | (25.47 M) | ||||
| Current Asset | 287.26 M | ||||
| Current Liabilities | 76.49 M | ||||
About Novavax Performance
Evaluating Novavax's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Novavax has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Novavax has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 15.75 | 16.54 | |
| Return On Tangible Assets | (0.13) | (0.14) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.12) | (0.13) | |
| Return On Equity | 0.30 | 0.29 |
Things to note about Novavax performance evaluation
Checking the ongoing alerts about Novavax for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novavax help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novavax had very high historical volatility over the last 90 days | |
| Novavax has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 682.16 M. Net Loss for the year was (187.5 M) with profit before overhead, payroll, taxes, and interest of 732.56 M. | |
| Novavax currently holds about 1.28 B in cash with (87.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Novavax has a poor financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: What analysts say about Novavax Inc. stock - Exceptional trading performance - Autocar Professional |
- Analyzing Novavax's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novavax's stock is overvalued or undervalued compared to its peers.
- Examining Novavax's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novavax's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novavax's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novavax's stock. These opinions can provide insight into Novavax's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.